Central Pharmaceutical Joint Stock Company No3 (DP3) Q1 2026 earnings summary

Executive summary

• Net revenue for Q1 2026 reached VND 134.98 billion, up 47% year-over-year from VND 91.90 billion.

• Profit after tax for Q1 2026 was VND 34.78 billion, a 46% increase compared to VND 23.86 billion in Q1 2025.

• Gross profit margin improved, with gross profit at VND 39.88 billion versus VND 31.04 billion last year.

Financial highlights

• Operating profit for Q1 2026 was VND 43.31 billion, up from VND 29.57 billion year-over-year.

• Financial income rose to VND 2.45 billion from VND 1.27 billion, while financial expenses increased to VND 582.6 million.

• Basic EPS for Q1 2026 was VND 1,618, up from VND 1,110 in Q1 2025.

• Total assets at March 31, 2026 were VND 795.05 billion, up from VND 756.09 billion at the start of the year.

• Cash and cash equivalents at quarter-end were VND 3.71 billion, down from VND 4.48 billion at year-beginning.

Outlook and guidance

• No explicit forward-looking guidance provided, but strong Q1 growth in revenue and profit signals positive momentum.